


ADOPTIVE CELL THERAPY

In 2019, an infographic on adoptive cell therapy was published. This is an updated presentation of the happenings in the field in the past five years (from 1/1/19)




What is ADOPTIVE Cell Therapy?




Currently, Trialtrrove classifies adoptive cell therapy (ACT) into three types with their own mechanism of action, namely ACT with tumor-infiltrating lymphocytes (TIL), ACT using T cell receptor (TCR) gene therapy, and ACT with chimeric antigen receptor modified T cells (CAR-T).

Trials initiated in past 5 years

Research reaches new high




Industry vs. non-industry sponsored trials and TOP 3 companies developing adoptive cell therapy




Geographic distribution

China and United States continue to hold the leading position in the ACT pipeline



Top 5 diseases per therapy



CAR-T therapy is the adoptive cell therapy that interests researchers the most for hematological cancers; non-Hodgkin's lymphoma tops the list. T-cell receptors and TIL therapies are being mostly studied in solid tumors.

4 CART drugs in the United States and 3 CART therapies in China granted approval for hematological cancers since 2019

In United States

- Lisocabtagene maraleucel
- Idecabtagene vicleucel
- Ciltacabtagene autoleucel
- Brexucabtagene autoleucel

In China

- Relmacabtagene autoleucel
- Equecabtagene autoleucel
- Inaticabtagene autoleucel



To learn more, visit [Citeline.com](https://www.citeline.com) or email clientservices@citeline.com

LEARN MORE

